This new formulation induces mitophagy by targeting endogenous TSPO and LC3, offering a novel approach to treating Down syndrome.657 These advancements highlight the potential of targeted cellular repair mechanisms in mitigating some effects of genetic disorders. Here, TSPO is linked to Down syndrome.